Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Use of bremelanotide in patients with controlled hypertension 2023-1-24 2023-5-25
DIAMINE-BINDED RECEPTOR-SPECIFIC CYCLIC PEPTIDES 2022-9-01 2022-10-31
Uses of bremelanotide in therapy for female sexual dysfunction 2022-7-14 2022-11-17
Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides 2022-7-12 2022-11-17
Orally Active Melanocortin Receptor-4 Compounds 2022-3-09 2022-6-30
Melanocortin receptor-specific peptide formulations and methods for … 2020-9-22 2021-8-16
Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation … 2020-7-13 2020-10-29
Therapies for Obesity, Diabetes and Related Indications 2020-5-19 2020-9-03
Melanocortin receptor-specific peptides 2019-1-11 2020-4-28 2020-4-28
Melanocortin-1 Receptor-Specific Linear Peptides 2017-2-02 2017-5-25
Replacement Therapy for Natriuretic Peptide Deficiencies 2016-11-10 2017-3-30
Melanocortin Receptor-Specific Peptides 2015-5-21 2015-9-10
Melanocortin Receptor-Specific Peptides for Treatment of Female Sexual … 2013-6-05 2013-10-31
Uses of Natriuretic Peptide Constructs 2012-10-17 2013-2-21
Lactam-bridged melanocortin receptor-specific peptides 2011-12-06 2016-3-01 2016-3-01
Peptidic Constructs with Amino Acid Surrogates 2011-6-17 2011-10-27
Melanocortin Receptor-Specific Spiro-Piperidine Compounds 2011-3-29 2011-7-21
Cyclic natriuretic peptide constructs 2010-2-04 2010-4-16
Amino acid surrogates for peptidic constructs 2010-1-14 2010-3-26
Amine substituted piperazine melanocortin receptor-specific compounds 2009-12-04 2010-6-10
Amine substituted piperidine melanocortin receptor-specific compounds 2009-12-04 2010-6-10
Substituted pyrrolidine or imidazolidine melanocortin receptor-specific … 2009-12-04 2010-7-29
Hydrazine substituted piperidine melanocortin receptor-specific compounds 2009-12-04 2010-6-10
Amide Linkage Cyclic Natriuretic Peptide Constructs 2009-10-02 2010-2-11
Small Molecule Compositions for Sexual Dysfunction 2009-6-19 2009-10-08
Melanocortin receptor-specific peptides for the treatment of obesity and other … 2009-6-08 2009-12-17
Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease … 2009-3-24 2009-12-17
Cyclic natriuretic peptide constructs 2008-10-27 2009-7-29
Amino acid surrogates for peptide constructs 2008-10-27 2009-8-26
Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics 2008-10-03 2009-3-12
Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds 2008-6-10 2008-10-16
Melanocortin receptor-specific compounds 2008-6-02 2011-6-21 2011-6-21
Mc4-r agonists for the treatment of obesity 2008-5-30 2009-12-03
Compounds and Methods for Treating Obesity 2008-5-30 2009-3-19
Methods for selection of melanocortin 4 receptor-specific agents for treatment … 2008-5-30 2009-12-03
Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of … 2008-5-30 2009-3-26
N, n; -substituted piperazines binding to melanocortin receptor 2008-1-24 2008-10-23
Diamine-containing, tetra- substituted piperazine compounds as melanocortin … 2007-8-10 2008-2-14
Diamine-containing, tetra-substituted piperazine compounds having identical 1- … 2007-8-10 2010-11-16 2010-11-16
TETRA- REPLACED PIPERAZINE COMPOUNDS CONTAINING DIAMINE AND HAVING 1 AND 4 … 2007-8-06 2008-10-22
Linear natriuretic peptide constructs 2007-3-30 2007-10-11
Pyrrolidine Melanocortin-Specific Compounds 2007-3-01 2007-7-05
Cyclic peptides for treatment of cachexia 2007-2-05 2008-8-27
N-Alkylated Cyclic Peptide Melanocortin Agonists 2006-11-07 2011-1-13
Cyclic peptide isolation by spray drying 2006-8-29 2007-3-08
Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds 2006-8-11 2006-12-21
Melanocortin receptor-specific piperazine compounds with diamine groups 2006-8-11 2011-6-28 2011-6-28
Melanocortin receptor-specific piperazine compounds with diamine groups 2006-8-11 2008-9-24
Melanocortin receptor-specific piperazine and keto-piperazine compounds 2006-8-11 2010-6-01 2010-6-01
Linear melanocortin receptor-specific peptides for cachexia 2006-7-05 2010-7-13 2010-7-13
Melanocortin receptor-specific compounds 2005-11-30 2006-10-25
Cyclic peptides for treatment of cachexia 2005-7-06 2006-12-14
Cyclic peptides for treatment of cachexia 2005-7-06 2006-2-09
Multiple agent therapy for sexual dysfunction 2005-5-27 2007-4-02
Multiple agent therapy for sexual dysfunction. 2005-5-27 2007-3-01
Substituted melanocortin receptor-specific piperazine compounds 2005-4-19 2010-5-04 2010-5-04
Substituted melanocortin receptor-specific piperazine compounds 2005-4-05 2010-5-18 2010-5-18
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds 2005-1-21 2010-2-02 2010-2-02
Naphthalene-containing melanocortin receptor-specific small molecule 2005-1-14 2010-6-08 2010-6-08
Peptide compositions for treatment of sexual dysfunction 2005-1-07 2005-6-09
Cyclic peptide compositions and methods for treatment of sexual dysfunction 2004-8-09 2006-6-14
Knockout identification of target-specific sites in peptides 2004-2-02 2004-9-10
Piperazine melanocortin-specific compounds 2004-1-21 2005-11-03
Piperazine melanocortin-specific compounds 2004-1-21 2008-4-08 2008-4-08
Bicyclic melanocorin-specific compounds 2004-1-21 2005-9-01
Linear and cyclic melanocortin receptor-specific peptides 2004-1-12 2008-8-26 2008-8-26
Melanocortin metallopeptides for treatment of sexual dysfunction 2003-8-13 2007-12-11 2007-12-11
Peptidomimetics of biologically active metallopeptides 2002-8-12 2003-6-19
Linear and cyclic melanocortin receptor-specific peptides 2002-7-11 2003-5-22
Identification of target-specific folding sites in peptides and proteins 2001-12-19 2004-1-04
IDENTIFICATION OF TARGETED FOLDING CENTERS IN PEPTIDES AND PROTEINS 2001-12-19 2008-3-27 2008-3-27
Identification of target-specific folding sites in peptides and proteins 2001-12-19 2002-8-28
Compositions for the treatment of sexual dysfunction 2000-6-29 2005-6-06 2005-6-06